华领医药-B:中期报告2025

香港交易所
Sep 25

牛牛AI助手已提取核心信息华领医药2025年上半年业绩表现强劲,华堂宁销量同比增长108%至176.4万盒,收入同比增长112%至人民币2.17亿元。毛利率由去年同期的46.5%提升至54.2%,主要受益于生产规模及效率提升。期内确认其他收入人民币12.4亿元,主要来自与拜耳终止推广合作关系后一次性结转递延收益,首次录得半年度盈利人民币11.8亿元。公司于2025年1月1日全面接管华堂宁在中国的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10